Breathe Well Live Well
|
MediciNova shares plunge as asthma drug fails in Ph IIb trial
The Pharma Letter MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … |
View full post on asthma – Google News
|
MediciNova shares crash after lead asthma drug fails IIb trial
FierceBiotech MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned … MediciNova asthma drug fails trial; shares crash MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … |
View full post on asthma – Google News
|
MediciNova asthma drug fails trial; shares crash
Reuters (Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a … MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News
|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
MarketWatch (press release) MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News
|
MediciNova To Release Asthma And COPD Trial Results In Q2
Seeking Alpha "We'll have Phase 2b results by the end of May treating patients with acute exacerbations of asthma (AEA) in the emergency room and results by June from a Phase Ib multi-dose trial in patients with moderate-to-severe chronic obstructive pulmonary … |
View full post on asthma – Google News
|
New drug can prevent exacerbations of asthma due to common cold: Trial report
News-Medical.net By Dr Ananya Mandal, MD For the tens of thousands of asthma sufferers in the UK there is a “breakthrough” drug that reduces complications caused by the common cold, it is claimed. Severe symptoms due to cold infections are one of the chief reasons why … Synairgen's 'breakthrough' asthma drug shines in Phase II trial Earlier trial with an unlicensed drug shows good relief in Asthma complications Scientists Hail Asthma Drug That 'Prevents Life-Threatening Symptoms' |
View full post on asthma – Google News
 Daily Mail |
Positive Results in Trial for New Asthma Treatment
news Stories Synairgen, a drug development company that spun out of the University of Southampton, United Kingdom, has announced positive results of a phase 2 clinical trial of its asthma drug SNG001. The trial investigated the potential for SNG001 to protect … Positive SNG001 Phase II Asthma Clinical Trial Data Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial |
View full post on asthma – Google News
Daily Mail |
Positive SNG001 Phase II Asthma Clinical Trial Data
Science 2.0 (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial New drug 'reduces asthma symptoms' |
View full post on asthma – Google News
|
Positive results trial for new asthma treatment
Medical Xpress This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive results in Southampton-led patient trial for new asthma treatment
Science Codex This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News